OGEN ORAGENICS INC

CIK 0001174940 50 ready 8-Ks latest July 6, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 6, 2026, 4:05 PM ET

Top materiality 0.75

Event mix other_material ×31 · leadership ×9 · other ×7

Sentiment 17 pos · 3 neg · 30 neu

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for OGEN

Highest-materiality recent filing

Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

May 19, 2026, 8:38 AM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.

Read filing →

July 6, 2026, 4:05 PM ET leadership materiality 0.65 neutral item 1.01 item 5.02 item 5.07 item 9.01

Oragenics appoints John Spencer as CFO; shareholders authorize reverse stock split

John Spencer appointed CFO effective July 1, 2026; base salary $200,000, option award of $25,000.
May 19, 2026, 8:38 AM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.
May 7, 2026, 7:59 PM ET M&A materiality 0.65 positive item 8.01 item 9.01

Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI

LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.
April 13, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury

First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.
March 11, 2026, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Oragenics gets HREC approval, starts Phase IIa site activation for ONP-002 in Australia; explores CNS asset acquisition

Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.
November 12, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial

Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.
October 21, 2025, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 3.01 item 7.01 item 9.01 ◈ Listing & Compliance Notices

Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance

Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.
August 11, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025

Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.
July 2, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants

Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.
May 28, 2025, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards

Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.
May 2, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 1.01 item 5.02 item 5.07 item 9.01

Oragenics appoints Janet Huffman as permanent CEO; shareholders authorize reverse stock split up to 1:50

Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.
January 21, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 8.01 item 9.01

Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline

CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.
January 17, 2025, 6:59 PM ET leadership materiality 0.70 neutral item 1.01 item 5.02 item 8.01 item 9.01 ◈ executive_change

Oragenics names CFO Janet Huffman Interim CEO at $275K salary; director resigns

Janet Huffman appointed Interim CEO effective Jan 16, 2025; salary increased 10% to $275,000 with $75,000 cash bonus.
December 16, 2024, 6:59 PM ET leadership materiality 0.75 neutral item 5.02 item 5.07 item 8.01 item 9.01

Oragenics appoints CFO Janet Huffman as Interim CEO; Preferred conversion cancels $2.35M liquidation preference

J. Michael Redmond terminated as Interim CEO/President effective Dec 16, 2024; CFO Janet Huffman appointed as new Interim CEO and President.
October 15, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Oragenics enters $10M ATM stock offering agreement with Dawson James

May sell up to $10M common shares at-the-market through Dawson James Securities.
October 9, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Oragenics updates on concussion drug ONP-002 progress; Phase II trial preparation advanced

ONP-002 cleared FDA cardiotoxicity and genotoxicity tests; spray-dry formulation completed with 4-fold drug increase per dose.
August 16, 2024, 7:59 PM ET other material materiality 0.75 negative item 3.01 item 8.01 item 9.01

Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024

NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.
August 12, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Oragenics: concussion drug ONP-002 shows no genotoxicity in animal study; Phase II planned

ONP-002 completed in vivo micronucleus assay; no evidence of genetic mutations or DNA damage across low, medium, high doses.
August 8, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Oragenics' concussion drug ONP-002 passes FDA cardiotoxicity test, Phase II planned

ONP-002 showed no cardiotoxicity in GLP hERG study conducted by Charles River Laboratories.
June 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Oragenics closes public offering of 1.1M shares at $1.00, raising $1.1M gross

Offering of 1,100,000 common shares at $1.00 per share closed on June 26, 2024.
May 16, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Oragenics preparing Phase II trial for concussion drug ONP-002; secures CRO, optimizes formulation

ONP-002 intranasal neurosteroid for mild TBI (concussion) advances to Phase II after positive Phase I safety.
May 7, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia

Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.
April 22, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 8.01 item 9.01 ◈ Listing & Compliance Notices

Oragenics receives NYSE American noncompliance notice; equity $3.2M below $4M/$6M thresholds

NYSE American notified Oragenics it fails continued listing standards due to stockholders' equity of $3.2M as of Dec 31, 2023.
March 18, 2024, 7:59 PM ET leadership materiality 0.60 positive item 8.01 item 9.01

Oragenics appoints Dr. James Kelly as CMO to lead Phase II concussion trial

Dr. Kelly will serve as CMO under an independent contractor agreement at $400/hour for 20 hours/month.
March 1, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Oragenics closes $2.1M public offering of 1.4M shares; funds ONP-002 development

Issued 1,400,000 shares at $1.50/share for gross proceeds of $2.1M.

Executive changes

Departed

Bruce Cassidy

director

OGEN · ORAGENICS INC

Effective: 2025-01-15
Filed: January 17, 2025, 6:59 PM ET

On January 15, 2025, Mr. Bruce Cassidy resigned as director of the Company to pursue other opportunities.

Appointed (interim)

Michael Redmond

Interim Principal Executive Officer

OGEN · ORAGENICS INC

Effective: 2024-02-12
Filed: February 12, 2024, 6:59 PM ET

In addition, effective February 12, 2024, the Board appointed Michael Redmond, the Company’s President, as the Company’s Interim Principal Executive Officer.

Role change (interim)

Charlie Pope

Executive Chairman

OGEN · ORAGENICS INC

Effective: 2024-02-12
Filed: February 12, 2024, 6:59 PM ET

The Board will provide direction to the Company during this transition in management, with Charlie Pope, the Company’s Chairman of the Board, serving, on an interim basis, as Executive Chairman, effective immediately.

Departed

Kimberly Murphy

Chief Executive Officer

OGEN · ORAGENICS INC

Effective: 2024-02-12
Successor: Michael Redmond
Filed: February 12, 2024, 6:59 PM ET

On February 12, 2024, Oragenics, Inc. (the “Company”) and Kimberly Murphy, the Company’s Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the “Separation Agreement”), pursuant to which Ms. Murphy’s employment with the Company terminated effective February 12, 2024.

Appointed

Joseph Michael Redmond

President

OGEN · ORAGENICS INC

Effective: 2023-12-28
Filed: December 29, 2023, 6:59 PM ET

the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company

Appointed

Bruce Cassidy

Director

OGEN · ORAGENICS INC

Effective: 2023-10-04
Filed: October 5, 2023, 7:59 PM ET

Following the increase in the size of the Company’s board of directors, the Board of Directors appointed Mr. Bruce Cassidy and Mr. John Gandolfo to the Company’s board.

Appointed

John Gandolfo

Director

OGEN · ORAGENICS INC

Effective: 2023-10-04
Filed: October 5, 2023, 7:59 PM ET

Following the increase in the size of the Company’s board of directors, the Board of Directors appointed Mr. Bruce Cassidy and Mr. John Gandolfo to the Company’s board.

Appointed

Janet Huffman

Chief Financial Officer

OGEN · ORAGENICS INC

Effective: 2023-03-07
Filed: March 8, 2023, 6:59 PM ET

announced that the Board of Directors approved the appointment of Janet Huffman, as the Company’s new Chief Financial Officer

Appointed (interim)

Kimberly Murphy

Interim Chief Financial Officer, Secretary and Treasurer

OGEN · ORAGENICS INC

Effective: 2022-12-15
Filed: December 16, 2022, 6:59 PM ET

Effective December 15, 2022, Ms. Kimberly Murphy, the Company’s President and Chief Executive Officer, was appointed Interim Chief Financial Officer, Secretary and Treasurer of the Company

Departed

Michael Sullivan

Chief Financial Officer, Secretary and Treasurer

OGEN · ORAGENICS INC

Effective: 2022-12-14
Successor: Kimberly Murphy
Filed: December 16, 2022, 6:59 PM ET

Michael Sullivan’s resignation as Chief Financial Officer, Secretary and Treasurer of the Company, to be effective December 14, 2022

Departed

Michael Sullivan

Chief Financial Officer

OGEN · ORAGENICS INC

Effective: 2022-12-14
Filed: November 16, 2022, 6:59 PM ET

On November 16, 2022, Michael Sullivan, the Chief Financial Officer of Oragenics (the “Company”) notified the Company that he would be resigning from the Company, effective December 14, 2022, to pursue other opportunities.

Appointed

Kimberly Murphy

President and Chief Executive Officer

OGEN · ORAGENICS INC

Effective: 2022-06-23
Filed: June 23, 2022, 7:59 PM ET

On June 23, 2022, Oragenics Inc. (the “Company”) announced that the Board of Directors approved the appointment of Kimberly Murphy, as the Company’s new President and Chief Executive Officer of the Company.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.57 · Most common event other_material

17 positive 3 negative 30 neutral

source · OGEN on sec.gov